Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig(R) (zolmitriptan) Nasal Spray

BRIDGEWATER, N.J., June 29, 2018 -- (Healthcare Sales & Marketing Network) -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that a panel of three Circuit Judges of the U.S. Court of Appeals for the Federal Circuit has affirmed the March 30, 20... Biopharmaceuticals, Generics, Litigation Amneal Pharmaceuticals, AstraZeneca, Lannett, Zomig, zolmitriptan
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news